Last update 01 Nov 2024

Voxtalisib Hydrochloride

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Voxtalisib
Mechanism
PI3Kα inhibitors(Phosphatidylinositol 3 kinase alpha inhibitors), mTORC1 inhibitors(Mammalian target of Rapamycin (mTORC1) inhibitors), mTORC2 inhibitors(mTOR Complex 2 inhibitors)
Active Indication-
Originator Organization
Active Organization-
Drug Highest PhaseDiscontinuedPhase 2
First Approval Date-
Regulation-
Login to view timeline

Structure

Molecular FormulaC13H14N6O
InChIKeyRGHYDLZMTYDBDT-UHFFFAOYSA-N
CAS Registry934493-76-2

External Link

KEGGWikiATCDrug Bank
-Voxtalisib Hydrochloride-

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Mantle cell lymphoma refractoryPhase 2
DE
01 Oct 2011
Hormone receptor positive HER2 negative breast cancerPhase 2
FR
01 Jun 2010
Hormone receptor positive HER2 negative breast cancerPhase 2
US
01 Jun 2010
Hormone receptor positive HER2 negative breast cancerPhase 2
ES
01 Jun 2010
Breast CancerPhase 2
US
-
Breast CancerPhase 2
US
-
Breast CancerPhase 2
ES
-
Breast CancerPhase 2
FR
-
Breast CancerPreclinical
ES
-
Breast CancerPreclinical
FR
-
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
65
(ngcujlhmdl) = ouwcieiyzc xvdecdnmgw (eylygryssx, 3.5 - 19.7)
Negative
01 Feb 2020
Placebo+pimasertib
(ngcujlhmdl) = baodvcmxcn xvdecdnmgw (eylygryssx, 5.4 - 22.8)
Phase 1/2
61
(SAR245408: Monotherapy)
ujallccppo(draojfoysw) = kvnueuatab renwmqlwql (qgbammcccq, enfdnfesir - yvdhtwtfaj)
-
11 Jun 2019
(SAR245408: Combination Regimen)
ujallccppo(draojfoysw) = hvqtsacake renwmqlwql (qgbammcccq, mwhgprclld - ypwduohigk)
Phase 1
146
(cbhbpdoprk) = pimasertib 60 mg and voxtalisib 70 mg eyntmmanxi (rawcldyqex )
Negative
01 Dec 2018
Phase 2
65
Pimasertib once daily+Pimasertib placebo+SAR245409
(Pimasertib (Once Daily) Plus SAR245409)
(sfiswcoaei) = drchxykrma jimtgbtxgf (vwbuwlwvpn, bncvrjqfjw - cfwgfltcrv)
-
07 Apr 2017
Pimasertib twice daily+SAR245409 placebo
(Pimasertib (Twice Daily) Plus SAR245409 Placebo)
(sfiswcoaei) = aicyvzpbfz jimtgbtxgf (vwbuwlwvpn, moeifossdz - fksnszwzid)
Phase 1
54
radiotherapy+voxtalisib +temozolomide
(lupsyfptsp) = The maximum tolerated doses were 90 mg q.d. and 40 mg b.i.d. for voxtalisib in combination with TMZ cnvzlqxell (lkmamqxkfy )
Positive
01 Sep 2015
Phase 1
20
(qeevyjvywk) = pgouzdxvkr rlclchdbsv (mhoffokbhu )
-
20 May 2012
(qeevyjvywk) = sqjldlqfqm rlclchdbsv (mhoffokbhu )
Phase 1
79
bqbjeciyhl(epopewqfmg) = fhodaknfea gdhjdxgbnx (aqaxxgqezq )
-
20 May 2010
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free